Title:Evolving Strategies for the Treatment of T-Cell Lymphoma: A Systematic Review and Recent Patents
Volume: 13
Issue: 3
Author(s): Kamel Laribi*, Mustapha Alani, Catherine Truong and Alix Baugier de Materre
Affiliation:
- Centre Hospitalier Le Mans, Department of Hematology, 194 Avenue Rubillard, 72000 Le Mans,France
Keywords:
Diagnosis, drug targeting, lymphoma, methods, new agent, patents, signaling pathway, T cell.
Abstract: Objective: Mature T-cell lymphomas are a heterogeneous group of T-cell malignancies with
a poor outcome. The discovery of new molecular biomarkers has led to the emergence of new drugs in
recent years that target various signaling pathways.
Methods: We examined all pertinent published patents through 2015 that analyzed novel methods for
the diagnosis and treatment of T cell lymphoma, as well as related published and unpublished studies.
Selection criteria were established before data collection. An exhaustive literature search was performed
using MEDLINE and Science Direct databases. The search criteria were T-cell lymphoma,
diagnosis, and treatment.
Results: Recent papers have identified recurrent epigenetic factor mutations in RHOA and FYN kinase
in PTCL allowing new perspectives for epigenetic-based therapy, molecular classification model using
CD28, ABCA5 transporter, coiled-coil domain-containing protein 3, and angiogenic factor SMOC2
biomarkers for differentiating forms of lymphomas, as well as expression of receptors forTNFR-1,
TNFR-2, and IL12p40/70 in CTCL. New therapeutic targets have been reported such as MicroRNAs -
155 inhibitors and synthetic Toll-Like Receptor 7/8 agonists for treating CTCL, Anti CTLA-4 antibodies,
anti- Killer cell immunoglobulin-like receptors 3DL2 and NK-p46 (NCR receptors) antibodies for
treating PTCL, Cd1d antagonist-restricted gamma/delta-T cell lymphomas, antiEZH2, novel antihistone
deacetylase, and NK cells engineered therapy.
In the transplantation setting, the objective was to eradicate overcoming of the residual disease immunity
and to induce an immune tolerance by anti-third part cells with a central memory T-lymphocyte
phenotype.
Conclusion: Therapeutic strategies based on a better molecular characterization of various histological
types are certain to be used in the future.
